CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Canatu Plc’s new series A shares subscribed for with investor warrants have been registered with the Finnish Trade Register

By Inderes

Canatu Plc                                             Company release                   10 November 2026 at 11:30 am EET

Canatu Plc’s new series A shares subscribed for with investor warrants have been registered with the Finnish Trade Register

During the subscription window of Canatu Plc’s (the “”) investor warrants between 1 July 2026 and 30 September 2026, a total of 42 new series A shares in the Company have been subscribed for with the investor warrants. Company

The aggregate subscription price of EUR 483.00 paid for the subscriptions made with the investor warrants will be entered in its entirety into the Company’s reserve for invested unrestricted equity.

As a result of the share subscriptions, the number of the Company’s series A shares is in total 33,779,786, the number of series B shares is in total 1,050,000 and the number of series C shares is in total 0. The total number of the Company’s shares and votes after the share subscriptions is 34,829,786.

The new series A shares subscribed for with the investor warrants have been registered with the Finnish Trade Register today, 10 November 2026. The new series A shares confer shareholder rights on their holders from the date of the registration. The new series A shares will be admitted to public trading on the Nasdaq First North Growth Market Finland marketplace maintained by Nasdaq Helsinki Oy together with the pre-existing series A shares on or about 11 November 2026.

The share subscription period for the investor warrants begun on 17 October 2024 and will end on 17 October 2029.

Additional information concerning the investor warrants is available on the Company’s website at: . https://canatu.com/investors/share-information/warrants-and-option-plans/

Additional information

Mikko Vesterinen, CFO, mikko.vesterinen@canatu.com

Dr. Maximilian Slawinski, CEO, maximilian.slawinski@canatu.com

Certified adviser

DNB Carnegie Investment Bank AB (publ), tel. +46 (0) 8 588 685 70

About Canatu

Canatu (CANATU, Nasdaq First North, Finland) is a deep technology scaleup company creating advanced carbon nanotubes (Canatu CNTs), related products, and manufacturing equipment for the semiconductor, robotics, mobility and defense, and medical diagnostics industries. Canatu partners with forerunner companies, together transforming products for better tomorrows with nano carbon.

Canatu’s versatile platform technology has broad potential applications. Its current core includes CNT membranes for extreme ultraviolet (EUV) processes in the semiconductor industry, enabling more effective manufacturing of the most advanced chips. Additionally, electrochemical sensors for medical diagnostics are in the development phase. Canatu’s patented CNT reactors and Dry Deposition by Canatu method yield clean and pristine CNTs. The company operates through two business models: selling CNT products directly, as well as selling CNT reactors and licensing the related technology so that customers can produce CNT products under a limited license. TM

Headquartered in Finland, Canatu also operates in the US, Japan and Taiwan. Founded in 2004 as a spin-off from Aalto University’s Nanomaterials Group, Canatu currently has 182 full-time equivalent employees representing over 35 nationalities, with nearly 20% holding or pursuing doctorates (as of 30 June 2026). Discover more at and follow us on . www.canatu.com LinkedIn

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.